ovarian cancer
Conditions
Interventions
Experimental group:Targeted Therapy + Jianpi Yangxue Decoction
Control Group:Targeted Therapy
Sponsors
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Female, aged 18 to 65 years; 2. Clinically diagnosed platinum-sensitive recurrent ovarian or fallopian tube cancer or primary peritoneal cancer (recurrence time >= 6 months from the last chemotherapy); 3. In accordance with the 2018 Chinese Ovarian Cancer Diagnosis and Treatment Standards, receive PARP inhibitor maintenance therapy after chemotherapy; 4. Patients with TCM syndrome type: spleen deficiency and blood deficiency type: pale complexion, fatigue and fatigue, shortness of breath, poor appetite, nausea and vomiting, irregular stool, pale tongue, thin white or greasy coating, thin and weak pulse. 5. Eastern Cooperative Oncology Group (ECOG) physical fitness score of 0 to 2; 6. Cardiac color ultrasound indicates that the cardiac ejection fraction is within the normal range; 7. Ability to swallow pills; 8. Patients with good organ function and meeting the following indicators and no contraindications to chemotherapy: (1) Hemoglobin >= 90g/L; (2) White blood cells >= 4.0 x 10^9/L; (3) Platelets >= 100 x 10^9/L; (4) Neutrophils >= 1.5 x 10^9/L; (5) Aspartate aminotransferase is not more than 3 times the upper limit of normal; (6) Alanine aminotransferase is not more than 3 times the upper limit of normal; (7) Bilirubin is not more than 1.5 times the upper limit of normal; (8) Serum creatinine value is not greater than 1.5 times the upper limit of normal.
Exclusion criteria
Exclusion criteria: 1. Combined with other malignant tumors or other malignant tumors in recent 5 years, except skin basal cell carcinoma or flat cell carcinoma and cervical carcinoma in situ which have been fully treated and controlled; 2. Serious diseases with non malignant tumors which will affect the patient's compliance or force the patient into a dangerous situation; 3. Accompanied by other anti-tumor treatments or participate in other clinical trials; 4. Pregnant or lactating women and those of childbearing age refuse to accept contraceptive measures; 5. Dementia, mental disorder or any mental illness that hinders the understanding of informed consent; 6. Severe liver dysfunction, child Pugh grade C, and or severe cardiac insufficiency, cardiac function grade III or above.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival;Adverse Effect; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life; | — |
Countries
China
Contacts
Public ContactZhu Tao
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Outcome results
None listed